CLINICAL PRACTICE

Clinical Vignettes

Going Skin Deep: Excavating a Diagnosis of Intravascular Large B Cell Lymphoma

Laura Oppegard, MD¹, Matthew O'Donnell, DO¹ , Kevin Piro, MD¹, Joseph Shatzel, MD², Robert Christian, MD³, Philipp W. Raess, MD, PhD³, and Sima Desai, MD¹

¹Department of Internal Medicine, Oregon Health & Science University, Portland, OR, USA; ²Division of Hematology-Oncology, Oregon Health & Science University, Portland, OR, USA; ³Department of Pathology, Oregon Health & Science University, Portland, OR, USA.

A fever of unknown origin is often pursued diagnostically under the framework of infectious, rheumatologic, and neoplastic causes. When encephalopathy ensues, the differential diagnosis narrows, but can remain elusive, particularly when dealing with rare diseases. We present the case of a patient with fever of unknown origin and intermittent encephalopathy that spanned multiple hospital admissions and ultimately yielded a diagnosis of intravascular large B cell lymphoma complicated by hemophagocytic lymphohistiocytosis. We review the varying presentations of this disease, when to consider this as a diagnosis, and how to most accurately make the diagnosis.

J Gen Intern Med 35(11):3368–71

DOI: 10.1007/s11606-020-06141-1

© Society of General Internal Medicine 2020

CASE

A 70-year-old Caucasian woman was admitted for evaluation of subacute fever of unknown origin associated with waxing-and-waning encephalopathy. This was her fourth admission in the last 4 months. She initially presented with weight loss and anemia; but over the ensuing months, she developed progressive nocturnal fevers, intermittent encephalopathy, visual hallucinations, and diplopia.

An extensive outside workup failed to identify a culprit infectious, neoplastic, or rheumatologic etiology. Notable labs showed a platelet count of 75 K/cu mm (normal, 150–400), hemoglobin of 7.7 g/dL (normal, 12–16), normal leukocyte count, ferritin of 3516 ng/mL (normal, 11–152), and erythrocyte sedimentation rate and C-reactive protein level of 112 mm/h (normal, 0–15) and 96.1 mg/L (normal, 0–10), respectively.

Diagnostic tests for infectious etiologies were all either normal or negative: plasma reagin for syphilis; PCR testing of blood samples for human immunodeficiency virus, Epstein-Barr virus, cytomegalovirus, herpes simplex virus, varicella zoster virus; respiratory viral panel, *Borrelia burgdorferi* IgG/IgM, *Bartonella henselae* IgG/IgM, and cryptococcal antigen. Results of diagnostic testing for rheumatologic causes of fever, including antinuclear

antibodies, antineutrophil cytoplasmic antibodies, anti-double-stranded DNA, thyroid-stimulating hormone, rheumatoid factor, were unremarkable. Lumbar puncture (LP) revealed colorless cerebrospinal fluid (CSF) with five nucleated cells (normal, 0–5 /MM3), elevated protein, 89 mg/dL (normal, 15–45), and negative gram stain and culture.

Antimicrobials were initiated for empiric treatment of aseptic meningitis; however, the patient's fevers continued despite treatment. Brain magnetic resonance imaging (MRI) revealed multifocal punctate diffusion restrictions in the pons, initially concerning central pontine myelinolysis despite persistent eunatremia throughout her hospital stay (Fig. 1). A cardioembolic source was considered, but transthoracic echocardiogram did not reveal a vegetation and the insults within the pons were not considered typical for a cardioembolic vascular distribution. Cross-sectional imaging of the chest, abdomen, and pelvis showed mild splenomegaly in the absence of significant lymphadenopathy. Given her progressive deterioration in mental status and ongoing, unexplained nocturnal fevers, the patient was transferred to a tertiary medical center for further evaluation. Upon arrival, the patient complained of visual hallucinations and double vision and was found to have a dysconjugate gaze with intermittent left eye esotropia. Repeat LP demonstrated elevated CSF protein and IgG levels (CSF IgG, 359 mg/dL; normal, 0–6.0). An expanded CSF evaluation, including an autoimmune encephalitis panel and flow cytometry, was normal. A second brain MRI revealed an interval increase in the number and size of lesions within the pons, with additional supratentorial lesions noted bilaterally (Fig. 2).

Serum ferritin remained persistently elevated at 8324 ng/mL (normal, 100–200). Despite the absence of lymphadenopathy on imaging, an underlying lymphoma was considered plausible given the patient's age, weight loss, persistent hyperferritinemia, and negative infectious disease workup. An elevated serum beta-2 microglobulin and lactate dehydrogenase (LDH) at 5.4 (normal, 1.1–2.4) and 605 u/L (normal, < 250), respectively, further supported this idea. Multidisciplinary discussion prompted evaluation for intravascular large B cell lymphoma (IVLBCL) and concomitant hemophagocytic lymphohistiocytosis (HLH) given these diagnoses could link

Received January 11, 2020

Accepted August 12, 2020

Published online August 19, 2020

Figure 1 MRI brain T2—hyperintensity lesions in the pons.

her cytopenias, elevated ferritin, and splenomegaly. Hemangioma skin biopsies revealed atypical CD20+ large lymphoid cells, clustered within capillaries, and post-capillary venules, consistent with a diagnosis of IVLBCL. Bone marrow biopsy identified a low-level (1%) monoclonal B cell population (CD 19+, CD20+) with clusters of atypical large B-cells and hemophagocytic histiocytes (Fig. 3). Fasting triglycerides returned elevated at 282 mg/dL (normal, < 150) and soluble IL-2 receptor was elevated at 11070 pg/mL (normal, < 1033) confirming the additional diagnosis of secondary HLH.

DISCUSSION

In almost every case of fever of unknown origin, there exists a pivot¹—a finding with a limited differential diagnosis, around which a clinician structures their diagnostic thinking. In this case, hyperferritinemia served as the pivot to frame and reorder the differential diagnosis. A retrospective analysis of 627 patients with a ferritin level > 1000 µg/L demonstrated that malignancy was the most frequent condition (24%) associated with hyperferritinemia, followed by iron overload (22%) and hepatocellular disease (17%).² When stratified by age, patients older than 50 years exhibited an increase in frequency of malignancy to 30.1%, a value that is not surprising given

cancer is the leading cause of death in women aged 45–84 years.³ Bearing in mind the patient's hyperferritinemia coupled with her age, gender, lack of liver dysfunction, and the base rate of disease, the differential was effectively narrowed, and the focus shifted to diagnostics to evaluate for hematologic malignancies.

IVLBCL is a rare variant of lymphoma characterized by proliferation of neoplastic lymphocytes within the lumen of small- to medium-sized vessels, with little to no involvement of peripheral blood or lymph nodes.⁴ Although a majority of patients present with nonspecific B-symptoms (fever, night sweats, weight loss), case reports of IVLBCL reveal highly variable clinical presentations.⁵

In the Western variant of IVLBCL, central nervous system (CNS) (39–76%) and cutaneous (17–39%) involvement are common, whereas HLH, bone marrow involvement, and hepatosplenomegaly, are common in Asian variants, particularly Japan.⁶ This case is unique in that neurologic involvement and secondary HLH were features of the patient's presentation.

CNS manifestations of IVLBCL, including neuropathies, paresthesias, aphasia, dysarthria, and altered conscious state, are present in approximately one-third of patients according to a case series of 38 patients.⁷ Brain MRI is an invaluable tool for the assessment of CNS intravascular involvement. The lesions associated with IVLBCL replicate findings in pontine osmotic demyelination syndrome and are speculated to be caused by vascular occlusion in small veins and arteries by tumor cells resulting in venous congestion that could manifest as hyperintensity in the central pons.⁸ The most common alternative diagnosis considered in cases with these MRI findings is CNS vasculitis. Lumbar puncture findings in IVLBCL rarely show malignant cells, whereas, like the index patient, increased cerebrospinal fluid protein levels are common.

HLH is a rare, life-threatening disorder associated with abnormal activation and proliferation of macrophages. The diagnosis is met if a culprit mutation in a known causative gene is identified or if at least 5 of 8 diagnostic criteria are met (Table 1).⁹ Persistent fevers, elevated ferritin, cytopenias, and

Figure 2 MRI brain T2—multiple small supratentorial diffusion restrictions.

Figure 3 Pathologic findings: **a** H&E skin biopsy showing large, atypical lymphoid cells (arrows) within vascular spaces. **b** Intravascular lymphoid cells stain positive for CD20. **c** Bone marrow aspirate showing increased hemophagocytic histiocytes (arrow). **d** Bone marrow clot H&E section showing groups of atypical lymphoid cells, which are positive for CD20 (inset).

splenomegaly sparked suspicion of HLH in this patient, but the diagnosis was confirmed with hypertriglyceridemia, elevated IL-2 receptor, and hemophagocytosis on bone marrow biopsy. Historically, HLH was associated with the Asian variant of IVLBCL, given the findings of one retrospective analysis of 173 patients in which HLH was absent in all 50 patients from Western countries.¹⁰ The present case is one of the few examples of a patient from a Western country with IVLBCL complicated by both HLH and CNS involvement.

Laboratory findings are not specific to the diagnosis of IVLBCL, but often LDH and beta-2 microglobulin are elevated and anemia is present.¹¹ The histopathology of IVLBCL is characterized by the presence of large, neoplastic lymphocytes in small- and medium-sized blood vessels.⁶ Although random skin biopsy (RSB) is an effective tool for establishing the diagnosis of IVLBCL, method and location appear to affect diagnostic yield. Atypical lymphoid cells are usually present in capillaries of subcutaneous adipose tissue; thus, some case reports speculate a higher diagnostic yield with biopsy of

hemangiomas compared with a random skin biopsy.¹² Although punch biopsy with 4 to 5 mm depth is traditionally used, a more recent report has suggested that approximately one-half of the patients diagnosed with IVLBCL only have lesions in deep adipose tissues found via incisional biopsy.¹³ (Fig. 3).

Treatment of the index patient required consideration of a three-pronged approach in order to address her intravascular lymphoma (IVLBCL), HLH, and underlying CNS involvement. Chemotherapy regimens are derived from the treatment of diffuse large B cell lymphoma using cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP).¹⁴ Due to the concomitant presence of HLH, our patient also received etoposide (R-EPOCH). The addition of etoposide is derived from the HLH-94 protocol, which guides the treatment of HLH using a combination of etoposide, dexamethasone, and intrathecal (IT) chemotherapy for CNS involvement.¹⁵ Following the first cycle of chemotherapy, the patient's mental status markedly improved from obtundation to alert, oriented, and participating in aspects of her care. She was ultimately discharged to a skilled nursing facility with the aim to complete six cycles of R-EPOCH and IT methotrexate.

This case highlights an unusual presentation of fever of unknown origin. An extensive workup over four hospital admissions hinged on the pivot provided by the patient's insidiously increasing serum ferritin, ultimately leading to the diagnosis of IVLBCL with CNS involvement and HLH. Any further delay in diagnosis would have undoubtedly been fatal. Timely recognition of this disease's various phenotypes and consideration of skin biopsy are essential in order to provide the necessary therapy for this treatable condition.

Table 1 HLH-2004 Diagnostic Criteria⁹

Five of the eight criteria listed below must be filled for HLH diagnosis	Criteria fulfilled by the index patient
1. Fever	Yes
2. Splenomegaly	Yes
3. Cytopenias (affecting 2 of 3 lineages in the peripheral blood)	Yes
4. Hypertriglyceridemia (fasting > 265 mg/dL) and/or hypofibrinogenemia (< 150 mg/dL)	Yes
5. Hemophagocytosis in bone marrow, spleen, lymph nodes, or liver	Yes
6. Low or absent NK-cell activity	No
7. Ferritin > 500 ng/mL	Yes
8. Soluble CD25 (i.e., IL-2 R) > 2400 U/mL	Yes

Corresponding Author: Matthew O'Donnell, DO; Department of Internal Medicine, Oregon Health & Science University, Portland, OR, USA (e-mail: odonnema@ohsu.edu).

Authors' Contribution All authors had access to the data and contributed to the writing of this manuscript.

Compliance with Ethical Standards:

Conflict of Interest: The authors declare that they do not have a conflict of interest.

REFERENCES

1. **Eddy DM, Clanton CH.** The art of diagnosis: solving the clinicopathological exercise. *N Engl J Med.* 1982;306(21):1263-1268.
2. **Moore C, Jr., Ormseth M, Fuchs H.** Causes and significance of markedly elevated serum ferritin levels in an academic medical center. *J Clin Rheumatol.* 2013;19(6):324-328.
3. Centers for Disease Control. Leading causes of death - females - all races and origins - united states, 2017 <https://www.cdc.gov/women/lcod/2017/all-races-origins/index.htm>. Published 2019, November 20 Accessed.
4. **Gatter K, Warnke R.** Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. In: Jaffe ES HN, Stein H, Vardiman JW, ed. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2001:177-178.
5. **Murase T, Nakamura S, Tashiro K,** et al. Malignant histiocytosis-like B-cell lymphoma, a distinct pathologic variant of intravascular lymphomatosis: a report of five cases and review of the literature. *Br J Haematol.* 1997;99(3):656-664.
6. **Ponzoni M, Ferreri AJ, Campo E,** et al. Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. *J Clin Oncol.* 2007;25(21):3168-3173.
7. **Ponzoni M, Ferreri AJ.** Intravascular lymphoma: a neoplasm of 'homeless' lymphocytes? *Hematol Oncol.* 2006;24(3):105-112.
8. **Yamamoto A, Kikuchi Y, Homma K, O'Uchi T, Furui S.** Characteristics of intravascular large B-cell lymphoma on cerebral MR imaging. *AJNR Am J Neuroradiol.* 2012;33(2):292-296.
9. **Henter JI, Horne A, Arico M,** et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer.* 2007;48(2):124-131.
10. **Ferreri AJ, Dognini GP, Campo E,** et al. Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. *Haematologica.* 2007;92(4):486-492.
11. **Ferreri AJ, Campo E, Seymour JF,** et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. *Br J Haematol.* 2004;127(2):173-183.
12. **Adachi Y, Kosami K, Mizuta N,** et al. Benefits of skin biopsy of senile hemangioma in intravascular large B-cell lymphoma: A case report and review of the literature. *Oncol Lett.* 2014;7(6):2003-2006.
13. **Enzan N, Kitadate A, Tanaka A, Matsue K.** Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B-cell lymphoma: a clinicopathological study of 25 patients. *Br J Dermatol.* 2019;181(1):200-201.
14. **Shimada K, Matsue K, Yamamoto K,** et al. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan. *J Clin Oncol.* 2008;26(19):3189-3195.
15. **Trottestam H, Horne A, Arico M,** et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. *Blood.* 2011;118(17):4577-4584.

Publisher's Note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.